Axogen Management
Management Kriterienprüfungen 2/4
Axogen CEO ist Michael Dale , ernannt in Aug 2024, hat eine Amtszeit von 1.75 Jahren. Die jährliche Gesamtvergütung beträgt $9.31M , bestehend aus 3.3% Gehalt und 96.7% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.12% der Aktien des Unternehmens, im Wert von $2.74M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.3 Jahre bzw. 4.3 Jahre.
Wichtige Informationen
Michael Dale
Geschäftsführender
US$9.3m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 3.26% |
| Amtszeit als Geschäftsführer | 1.8yrs |
| Eigentum des Geschäftsführers | 0.1% |
| Durchschnittliche Amtszeit des Managements | 2.3yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 4.3yrs |
Jüngste Management Updates
Recent updates
Axogen, Inc. (NASDAQ:AXGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$50.78
Apr 30
AXGN: BLA Approval And Market Expansion Will Shape Balanced Risk Reward Outlook
Narrative Update on Axogen Axogen's updated fair value estimate has moved by about $0.67, with analysts pointing to higher price targets around $40 to $42, supported by Avance Nerve Graft's FDA BLA approval, broader market expansion plans, and recent coverage highlighting its differentiated position in peripheral nerve repair. Analyst Commentary Recent research commentary on Axogen has focused heavily on the FDA BLA approval for Avance Nerve Graft, higher price targets around the low $40 range, and the company’s focus on expanding into new clinical markets.AXGN: BLA Approval Will Support Broader Peripheral Nerve Repair Adoption
Narrative Update on Axogen Axogen's analyst price targets have shifted higher into the low $40s, with analysts pointing to recent FDA BLA approval for Avance Nerve Graft, broader market expansion plans, and reduced risk following an equity raise as key supports for their updated views. Analyst Commentary Recent research on Axogen has centered on the FDA BLA approval for Avance Nerve Graft, the equity raise, and the company’s focus on peripheral nerve repair.AXGN: BLA Approval Should Support Wider Nerve Repair Market Adoption
Analysts have nudged Axogen's fair value estimate higher, with the blended price target moving from about $39.20 to roughly $40.56 as recent FDA BLA approval for Avance Nerve Graft and broader market expansion potential support more constructive views on growth and profitability. Analyst Commentary Recent research updates cluster around a more constructive view of Axogen following FDA BLA approval for Avance Nerve Graft and a clearer path to broader market coverage and adoption.AXGN: BLA Approval And Equity Raise Will Support 2026 Nerve Repair Rollout
Axogen's analyst price target moves higher, with recent Street research pointing to a range of $40 to $42 as analysts highlight the FDA BLA approval for Avance Nerve Graft, expanded market opportunities, and expectations for sustained revenue growth and improving profitability. Analyst Commentary Recent research updates cluster around the FDA BLA approval for Avance Nerve Graft and how it could influence Axogen's growth, profitability, and valuation over time.AXGN: Follow On Equity Raises Will Support Bullish 2025 Outlook
Analysts have slightly trimmed their average price target for Axogen, now reflecting a modestly lower assumed future P/E multiple while keeping fair value estimates around $37.33 and making only marginal adjustments to the discount rate, revenue growth, and profit margin assumptions. What's in the News Axogen filed a follow on equity offering of up to $85 million in common stock, providing additional access to equity capital if the company chooses to proceed with the full amount.AXGN: FDA Approval And Capital Raises Will Shape 2025 Outlook
Analysts have nudged their price target for Axogen slightly higher to reflect a modest uptick in fair value estimates to about $37.33. This move is supported by marginally stronger assumptions for profit margins and a slightly lower discount rate, while other pricing inputs, such as future P/E expectations, remain roughly in line with prior views.AXGN: Q3 Execution And 2025 Outlook Will Support Higher Confidence
Analysts have nudged their fair value estimate for Axogen higher to US$37.00 from US$35.44, citing recent price target increases following Q3 outperformance and raised 2025 guidance as support for this updated view. Analyst Commentary Recent research updates cluster around Axogen's Q3 performance and refreshed 2025 outlook, with multiple price target revisions framing how analysts are thinking about valuation, growth, and execution risk.AXGN: Q3 Execution Will Support Confidence In Raised 2025 Outlook
Analysts have nudged their average price target on Axogen higher, lifting it by a few dollars per share into the mid 20 dollar range. They cite the company's Q3 sales beat, increased 2025 growth outlook, and continued confidence in its market development strategy as key drivers of sustained revenue expansion.AXGN: Market Development Progress Will Support Confidence In 2025 Outlook
Axogen's analyst price target has been raised materially, increasing from about $29 to roughly $35. Analysts cite a Q3 beat, an improved 2025 sales growth outlook of at least 19 percent year over year, and continued confidence that the company’s market development strategy will support faster revenue growth even as margins normalize.AXGN: Execution And Upgraded Outlook Will Support Measured Momentum Ahead
Analysts have raised their price target for Axogen by $0.63 to $29.13, citing better-than-expected third-quarter performance and a strengthened sales outlook that is expected to drive anticipated growth in the coming years. Analyst Commentary Bullish analysts have responded positively to Axogen's recent performance and guidance updates.Returns Are Gaining Momentum At Axogen (NASDAQ:AXGN)
Nov 27AXGN: Strong Execution Will Drive Revenue Momentum With Upgraded 2025 Outlook
Axogen’s analyst price target has increased from $27.38 to $28.50 per share. Analysts cite strong quarterly results and higher fiscal 2025 growth guidance as supporting factors for this upward revision.Axogen, Inc. (NASDAQ:AXGN) Looks Just Right With A 30% Price Jump
Nov 04AXGN: Strong Sales Momentum And Upcoming FDA Decision Will Drive Future Upside
Axogen’s analyst price target has increased from $24.71 to $27.38. Analysts cite robust third-quarter performance and a heightened growth outlook for 2025 as the key drivers behind their upward revisions.Axogen (NASDAQ:AXGN) Has A Pretty Healthy Balance Sheet
Sep 12Axogen, Inc.'s (NASDAQ:AXGN) Shares Leap 29% Yet They're Still Not Telling The Full Story
Jul 23BLA Approval Will Secure 12-Year Exclusive Market Position
Anticipated product approval and targeted commercial expansion are driving increased market share, revenue growth, and improved profitability potential.Axogen, Inc. (NASDAQ:AXGN) Might Not Be As Mispriced As It Looks After Plunging 32%
May 10Would Axogen (NASDAQ:AXGN) Be Better Off With Less Debt?
Apr 17Shareholders Should Be Pleased With Axogen, Inc.'s (NASDAQ:AXGN) Price
Mar 26Is Axogen (NASDAQ:AXGN) Using Too Much Debt?
Jan 14Axogen: Well Placed To Capitalize Growth At Higher Multiples
Jan 07Axogen, Inc. (NASDAQ:AXGN) Looks Just Right With A 29% Price Jump
Dec 24Even With A 28% Surge, Cautious Investors Are Not Rewarding AxoGen, Inc.'s (NASDAQ:AXGN) Performance Completely
Sep 14Would AxoGen (NASDAQ:AXGN) Be Better Off With Less Debt?
Aug 20A Piece Of The Puzzle Missing From AxoGen, Inc.'s (NASDAQ:AXGN) 28% Share Price Climb
Jul 29Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$31m |
| Dec 31 2025 | n/a | n/a | -US$16m |
| Sep 30 2025 | n/a | n/a | -US$2m |
| Jun 30 2025 | n/a | n/a | -US$5m |
| Mar 31 2025 | n/a | n/a | -US$7m |
| Dec 31 2024 | US$9m | US$303k | -US$10m |
Vergütung im Vergleich zum Markt: MichaelDie Gesamtvergütung ($USD9.31M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD5.47M).
Entschädigung vs. Einkommen: Unzureichende Daten, um die Vergütung von Michael mit der Unternehmensleistung zu vergleichen.
Geschäftsführer
Michael Dale (65 yo)
Mr. Michael D. Dale is CEO & Director of AxoGen, Inc. from August 9, 2024 and also serves as its President since 2025. Mr. Dale served as the Chief Executive Officer and President of GI Dynamics, Inc. sinc...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| President | 1.8yrs | US$9.31m | 0.12% $ 2.7m | |
| Executive VP | 3.2yrs | US$1.85m | 0.094% $ 2.2m | |
| Chief Marketing Officer | 3.3yrs | US$1.75m | 0.14% $ 3.3m | |
| Chief Innovation Officer | 2.3yrs | US$2.27m | 0.45% $ 10.3m | |
| Chief Financial Officer | 1yr | keine Daten | 0.11% $ 2.6m | |
| Vice President of Operations | no data | keine Daten | keine Daten | |
| Vice President of Finance & Investor Relations | no data | keine Daten | keine Daten | |
| Vice President of Sales | 4.3yrs | keine Daten | keine Daten | |
| Chief Medical Officer | 2.3yrs | keine Daten | keine Daten |
Erfahrenes Management: AXGNDas Führungsteam des Unternehmens gilt als erfahren (2.3 Jahre durchschnittliche Betriebszugehörigkeit).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| President | 1.8yrs | US$9.31m | 0.12% $ 2.7m | |
| Independent Chairman of the Board | 5.7yrs | US$253.15k | 0% $ 0 | |
| Member of Board of Advisor | no data | keine Daten | keine Daten | |
| Member of Board of Advisor | no data | keine Daten | keine Daten | |
| Independent Director | 4.8yrs | US$217.50k | 0% $ 0 | |
| Independent Director | 2.4yrs | US$210.01k | 0% $ 0 | |
| Independent Director | 7yrs | US$217.50k | 0.069% $ 1.6m | |
| Independent Lead Director | 9.7yrs | US$259.01k | 0.16% $ 3.8m | |
| Independent Director | 3.8yrs | US$222.00k | 0.00019% $ 4.4k | |
| Independent Director | 3.4yrs | US$207.00k | keine Daten |
Erfahrener Vorstand: AXGNDie Vorstandsmitglieder gelten als erfahren (4.3 Jahre durchschnittliche Amtszeit).
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/01 22:54 |
| Aktienkurs zum Tagesende | 2026/05/01 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Axogen, Inc. wird von 18 Analysten beobachtet. 9 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Caitlin Cronin | Canaccord Genuity |
| David Turkaly | Citizens JMP Securities, LLC |
| Christopher Pasquale | Guggenheim Securities, LLC |